The tablet formulation of zanubrutinib (Brukinsa; BeOne) is currently permitted for all 5 indications throughout a number of hematological cancers.The modified stem cells supply the body with myeloid (immune) cells that produce the ARSA enzyme, which allows stop working the unsafe build-up of sulfatides and will stop the progression of MLD.  Ahead